Immune cell 'Fitness' may predict success of advanced myeloma therapies in older patients

NCT ID NCT07674498

Recruiting now Knowledge-focused Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates whether the health of a patient's immune cells can predict how well they will respond to CAR-T or bispecific antibody treatments for relapsed multiple myeloma. Researchers will analyze blood samples from patients aged 65 and older before they start standard therapy, looking at markers of immune cell aging and exhaustion. The goal is to combine immune profiles with frailty assessments to better personalize treatment for older adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors predict which older patients will benefit most from advanced immunotherapies, leading to more personalized treatment plans.
What could go wrong: This is an observational study, not a treatment trial. It aims to gather information, not test a new therapy, so it will not directly improve outcomes for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

CHU Saint-Pierre
NOT_YET_RECRUITING

Brussels, Brussels Capital, 1000, Belgium
Institut Jules Bordet
RECRUITING

Anderlecht, Brussels Capital, 1070, Belgium
institut roi albert II
NOT_YET_RECRUITING

Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.